Design and Screening of the Peptide SAMP-12aa Derived from LL-37, Which Exhibits Anti-H. Pylori Activity and Immunomodulatory Effects

Jiangbo Lu, Qi Wang, Meisong Qin, Jinfeng Dou, Youyi Xiong, Xue ZhangMolecules 2026 · DOI

TL;DR

This paper introduces SAMP-12aa, a novel peptide derived from human cathelicidin LL-37, which effectively kills Helicobacter pylori (H. pylori) and exhibits promising immunomodulatory effects. This dual action offers a potential new strategy to combat antibiotic-resistant H. pylori infections and modulate the immune response that contributes to its persistence.

What Problem Does This Paper Address?

Helicobacter pylori (H. pylori) is a common bacterial pathogen that can lead to serious gastrointestinal issues, including ulcers and gastric cancer. The standard treatment involves a combination of antibiotics and proton pump inhibitors. However, H. pylori is increasingly developing resistance to these antibiotics, leading to treatment failures and a growing public health concern. Furthermore, H. pylori infection can trigger an immune response that paradoxically promotes its long-term colonization by inducing immunosuppressive regulatory T (Treg) cells. There's a critical need for new therapeutic agents with novel mechanisms of action that can overcome antibiotic resistance and potentially modulate the host immune response to clear the infection.

Methods

The researchers designed and screened 28 short peptides based on fragments of the human antimicrobial peptide LL-37, aiming for stability in the harsh gastric environment. Key techniques included:

  • Peptide Design and Screening: 28 peptides of 12 amino acids were designed, incorporating a stable 9-amino acid core from LL-37 and adding 3 amino acids at the C-terminus. Stability in simulated gastric juice and anti-H. pylori activity (MIC and MBC) were evaluated.
  • Antibacterial Assays: Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) were determined for the most promising peptide, SAMP-12aa, against H. pylori. Bactericidal kinetics were assessed in both physiological saline and artificial gastric juice.
  • Mechanism of Action Studies:
    • Outer Membrane Permeability: The fluorescent probe NPN was used to assess SAMP-12aa's ability to disrupt the H. pylori outer membrane.
  • Cell Membrane Integrity: Propidium iodide (PI) staining was employed to visualize damage to the bacterial inner membrane.
  • Resistance Studies: H. pylori was repeatedly exposed to subinhibitory concentrations of SAMP-12aa and conventional antibiotics to assess the development of resistance.
  • Therapeutic Index and Cytotoxicity: Hemolytic activity on human red blood cells and cytotoxicity against human gastric adenocarcinoma cells were evaluated to determine the peptide's safety and selectivity.
  • Immunomodulatory Studies:
    • Molecular Docking: Computational analysis was used to predict the interaction of SAMP-12aa with the active site of Foxp3, a key transcription factor for Treg cell development.
  • Flow Cytometry: The effect of SAMP-12aa on CD4+ T cells, specifically the expression of CD25 and Foxp3, was analyzed to assess its impact on Treg cell differentiation.
  • ELISA: Cytokine levels (IFN-γ and TGF-β) in coculture supernatants were measured to evaluate the peptide's influence on cellular immune activation and suppression.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from bacterial cultures, cell lines, and biological assays.

Key Insights and Ideas

  • Dual-Action Peptide: The discovery of SAMP-12aa, a peptide that not only kills H. pylori but also modulates the host immune response, is a significant breakthrough. This dual functionality could offer a more comprehensive approach to treating H. pylori infections.
  • Gastric Stability is Key: Designing peptides that remain active in the acidic and enzyme-rich environment of the stomach is crucial for oral drug development. SAMP-12aa's stability in simulated gastric juice is a major advantage.
  • Novel Antibacterial Mechanism: SAMP-12aa's ability to disrupt bacterial cell membranes offers a mechanism less prone to resistance development compared to traditional antibiotics that target specific enzymes or pathways.
  • Targeting Immune Tolerance: The peptide's ability to inhibit Foxp3 and downregulate CD25 expression on Treg cells directly addresses the immune tolerance that allows H. pylori to persist. This is a sophisticated approach to clearing the infection.
  • Promising Safety Profile: The low toxicity to human cells and a high therapeutic index suggest that SAMP-12aa could be a safe and effective therapeutic agent.

Key Results

  • Potent Anti-H. pylori Activity: SAMP-12aa demonstrated a Minimum Inhibitory Concentration (MIC) of 8 µg/mL and a Minimum Bactericidal Concentration (MBC) of 32 µg/mL against H. pylori.
  • Stability in Gastric Juice: The peptide retained its anti-H. pylori activity and bactericidal kinetics even after incubation in simulated gastric juice.
  • Bactericidal Mechanism: SAMP-12aa effectively permeabilized the H. pylori outer membrane and destroyed the integrity of the inner cell membrane.
  • No Resistance Development: In vitro studies showed that H. pylori did not develop resistance to SAMP-12aa after repeated exposure.
  • High Therapeutic Index: The peptide exhibited a favorable therapeutic index, indicating good selectivity for bacterial cells over human cells.
  • Low Cytotoxicity: SAMP-12aa showed minimal toxicity to human gastric adenocarcinoma cells, even at relatively high concentrations.
  • Immunomodulatory Effects:
    • Molecular docking predicted a high affinity and specificity for binding to the Foxp3 active site.
  • Flow cytometry confirmed that SAMP-12aa reduced the population of immunosuppressive CD4+CD25High Treg cells.
  • ELISA showed that SAMP-12aa increased IFN-γ (pro-inflammatory) and decreased TGF-β (immunosuppressive) cytokine levels, promoting cellular immune activation.

Limitations and Future Work

  • In Vitro Focus: While promising, the study is largely based on in vitro experiments. Further in vivo studies are needed to confirm efficacy and safety in animal models and eventually in human clinical trials.
  • Specific H. pylori Strains: The study focused on specific H. pylori strains. Testing against a broader range of clinical isolates, including those with known resistance mechanisms, would be beneficial.
  • Delivery and Formulation: The paper does not delve into the specifics of how SAMP-12aa would be formulated or delivered for optimal therapeutic effect, especially considering its stability in gastric juice.
  • Long-Term Effects: The long-term impact of SAMP-12aa on the gut microbiome and host immune system requires further investigation.

The authors suggest that SAMP-12aa has significant potential as a new therapeutic agent for H. pylori infection, offering a novel approach that combines direct antibacterial action with immune modulation. Future work would likely focus on preclinical and clinical development.

Summary updated

Abstract

The appearance of antibiotic-resistant strains of Helicobacter pylori (H. pylori) is leading to a decreased eradication rate of H. pylori infection. There is an urgent need to find new agents with antimicrobial mechanisms different from those of antibiotics, with therapeutic potential to clear colonization of H. pylori in the stomach. Some antimicrobial peptides (AMPs) possess bactericidal activity by enhancing the permeability of the outer membrane and damaging the integrity of the cell membrane. Bacteria are not susceptible to drug resistance through this antimicrobial mechanism. In this study, 28 short peptides containing 12 amino acid residues were designed based on nine amino acid fragments (KRIVQRIKD) from human cathelicidin LL-37, which is stable in gastric juice, and 3 amino acids were added at the C-terminus of the peptide. These designed peptides were not digested and degraded by pepsin at low pH values. The peptides were predicted using the online tool platform. Then, the strongest antimicrobial peptide, named SAMP-12aa (KRIVQRIKDVIR), was screened from 28 short peptides. Further studies found that SAMP-12aa retained anti-H. pylori activity after incubation in simulated gastric juice. The MIC and MBC of SAMP-12aa were 8 μg/mL and 32 μg/mL, respectively. SAMP-12aa showed good bactericidal kinetics. SAMP-12aa was found to have cell selectivity, penetrating and damaging bacterial cell membranes and exhibiting almost no toxicity to human cells at a relatively high concentration (128 μg/mL). Regulatory T (Treg) cells express CD25High with immunosuppressive activity that induces immune tolerance in response to H. pylori. Molecular docking prediction revealed that SAMP-12aa could target the active center of Foxp3. Flow cytometry analysis revealed that SAMP-12aa can inhibit Foxp3 activity and downregulate CD25 protein expression on CD4+ T cells, thereby reducing the development and differentiation of CD4+Foxp3+CD25High Treg cells with immunosuppressive effects. Further research revealed that the levels of the cytokine interferon-γ (IFN-γ), which activates CD8+ T-cell activity, were significantly elevated, and the levels of transforming growth factor-β (TGF-β), which inhibits CD8+ T-cell activity, were significantly reduced. The results of this study reveal that SAMP-12aa not only possesses antibacterial activity but also has immunomodulatory effects.
BibTeX
@inproceedings{lu2026design,
  author = {Jiangbo Lu and Qi Wang and Meisong Qin and Jinfeng Dou and Youyi Xiong and Xue Zhang},
  title = {{Design and Screening of the Peptide SAMP-12aa Derived from LL-37, Which Exhibits Anti-H. Pylori Activity and Immunomodulatory Effects}},
  booktitle = {Molecules},
  year = {2026},
  doi = {10.3390/molecules31061002},
}
Figure